NasdaqGM:HELPPharmaceuticals
Cybin (HELP) Is Up 19.8% After Deepening Psychedelic Pipeline And Leadership Shift Is The Risk Story Changing?
In August 2026, Cybin Inc. reported a first-quarter net loss of US$47.82 million, with basic and diluted loss per share from continuing operations of US$0.91, while Helus Pharma appointed experienced HR leader Regina Donohue as Chief People Officer and CNS drug-development expert Suresh Durgam, M.D., to its Scientific Advisory Board.
Investor interest in Cybin has been influenced by its psychedelic medicine pipeline progress, including HLP003 entering a Phase 3 trial for major depressive...